Dr. Danxin Wang has a position as an associate professor and is currently working at the Department of Pharmacotherapy and Translational Research, University of Florida. She received her MD degree from Fudan University Medical School and her Ph.D. from the Academy of Military Medical Science in Beijing. She conducted postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics, and Associate Director of the Center for Pharmacogenomics prior to joining the University of Florida. Her research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases, and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response. Funded by NIH R01 and R35 awards, her current research is focused on understanding factors controlling the expression of cytochrome P450 drug metabolizing enzymes (CYPs) in the liver. She has served as an Associate Editor of the “European Journal of Pharmaceutical Sciences” and was on the Editorial Board of the “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as a grant reviewer for NIH.